### CME Credits:
Credits for Specialists: This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada, and approved by Queen’s University.

### Learning Objectives:
- To integrate current knowledge regarding molecular biology and new therapeutics in clinical trials evaluating radiotherapy
- To review relevant data from clinical studies evaluating radiotherapy interventions conducted by the Canadian Cancer Trials Group or its collaborators
- To integrate current statistical methodologies in clinical trial design
- To provide a learning environment supportive to investigators

### Schedule

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Presenter(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 am</td>
<td>Welcome</td>
<td>M. McKenzie</td>
</tr>
<tr>
<td>8:05 am</td>
<td>Preoperative Chemoradiotherapy vs. Preoperative Chemotherapy for Resectable Gastric Cancer.</td>
<td>R. Wong</td>
</tr>
<tr>
<td>8:10 am</td>
<td>SBRT vs. Conventional Palliative Radiotherapy for Spinal Metastases.</td>
<td>S Myrehaug</td>
</tr>
<tr>
<td>8:15 am</td>
<td>Phase II randomized study comparing HDR vs LDR monotherapy in localized prostate cancer.</td>
<td>W. Parulekar</td>
</tr>
<tr>
<td>8:20 am</td>
<td>Randomized study of single 8 Gy versus BSC for symptomatic primary or metastatic liver cancer.</td>
<td>R. Wong</td>
</tr>
<tr>
<td>8:25 am</td>
<td>TAILOR RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer.</td>
<td>V. Theberge</td>
</tr>
<tr>
<td>8:30 am</td>
<td>A Phase III Trial of Stereotactic Radiosurgery Compared with Whole Brain Radiotherapy (WBRT) for 5-15 Brain Metastases</td>
<td>D. Roberge</td>
</tr>
<tr>
<td>8:35 am</td>
<td>A Phase II Single Arm Trial of Elective Volume Adjusted De-Escalation Radiotherapy (EVADER) in Patients with Low-risk HPV-related Oropharyngeal Squamous Cell Carcinoma.</td>
<td>S. Bratman</td>
</tr>
</tbody>
</table>
8:40 am Randomized Phase II Study of Cisplatin + RT vs Durvalumab + RT followed by Adjuvant Durvalumab vs Durvalumab + RT followed by Adjuvant Tremelimumab and Durvalumab in Intermediate Risk HPV-Positive Locoregionally Advanced Oropharyngeal Squamous Cell Ca (LA-OSCC). **HN.9**

**Updates on CCTG approved studies**

8:45 am NRG HN004: Randomized phase II/III trial of Radiotherapy with Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy with Concurrent Cetuximab in Patients with Stage III-IVB Head and Neck Cancer With a Contraindication to Cisplatin. **HNC.2**

8:50 am PLATON: A Randomized Phase III Trial of Local Ablative Therapy For Hormone Sensitive Oligometastatic Prostate Cancer. **PR.20**

8:55 am ANZUP 1801: Darolutamide to Augment Standard Therapy for Localized High-Risk Cancer of the Prostate (DASLHiCaP) – A Randomized Phase III Trial of Adding Darolutamide to Radiation and Androgen Deprivation Therapy In High Risk Clinically Localized Prostate Cancer. **PR.22**

9:00 am S1827: A Randomized Phase III Trial of MRI Surveillance With or Without Prophylactic Cranial Irradiation in Small-Cell Lung Cancer. **BRC.8**

**Updates on previously discussed studies/proposals**

9:05 am Stereotactic Pelvic Adjuvant Radiation Therapy in Cancers of the Uterus (SPARTACUS) **E. Leung**

9:15 am SBRT for non-spine metastasis **I. Poon**

9:25 am PSMA-PET Guided Radiotherapy in Patients with High-risk, Recurrent, or Oligometastatic Prostate Cancer **H. Bahig**

9:35 am **Coffee Break**

**New Study proposals**

10:00 am ProMisE for endometrial cancer management **K. Han**

10:20 am Neoadjuvant RT +/- Immunotherapy for Squamous Cell Cancer of the Head and Neck **M Gaudet**

10:40 am VOCAL: Vocal-Cord Only vs Complete Laryngeal Radiation: A Randomized Multicentric Bayesian Phase II Trial **H. Bahig**

11:00 am SHORT-OPC: Stereotactic boost and SHOrt-course Radiation Therapy for HPV-associated OroPharynx Cancer trial **H. Bahig**

11:20 am A randomized trial of WBRT compared with targeted radiation treatment for patients with poor prognosis **A. Nichol**

11:40 am Activities of the Radiation Oncology Quality Assurance Committee **A. Nichol**

11:50 am **Meeting Adjourned**